Clinical trials
Lupus or SLE clinical trials
Below are recruiting lupus or sle clinical trials, each written for real people, not researchers. We’re tracking 333 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07086989Recruiting
Heart health study for kids with chronic conditions
This study looks at heart disease risk in children and young adults (ages 6-25) with long-term health conditions like certain heart, kidney, or diabetes disorders. The goal is to better understand and manage heart risks early.
BudapestAges 6–25 - NCT07085104RecruitingPhase 1
Study of ALLO-329 for lupus, myositis, or scleroderma
This trial tests a new one-time cell therapy (ALLO-329) made from donor cells to target and calm overactive immune cells in people with lupus, myositis, or scleroderma that hasn't improved with usual medications. It aims to see if this treatment is safe and can help reduce disease activity.
Phoenix, ArizonaAges 18–74 - NCT07077304Recruiting
Cardiac imaging study for inflammatory heart diseases
This study uses heart scans (MRI or nuclear imaging) to better understand inflammatory heart conditions. If you have a suspected inflammatory heart disease and are already scheduled for one of these scans, you may be able to join.
ParisAges 18 years+ - NCT07053891Recruiting
Safety survey of LUPKYNIS for lupus nephritis
This study is a safety survey for people who are just starting to take LUPKYNIS for lupus nephritis, a type of kidney inflammation caused by lupus. It aims to collect information on how well the drug works and any side effects in real-world use.
Osaka, OsakaAges 15 years+ - NCT07049653Recruiting
Anifrolumab pregnancy safety study
This study looks at pregnancy outcomes in women with lupus (SLE) who were or were not treated with the drug anifrolumab. It helps understand if anifrolumab is safe to use during pregnancy.
Cary, North CarolinaAges 18–130 - NCT07038382RecruitingPhase 2
Study of HLX79 with Rituximab for Active Kidney Disease
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
BeijingAges 18–75 - NCT07000110Recruiting
Anifrolumab and risk study for lupus patients
This study looks at potential risks of the lupus medication anifrolumab in people with moderate to severe SLE. It focuses on serious infections and malignancies to see how safe the treatment is.
CopenhagenAges 18–130 - NCT07000916Recruiting
Follow-up study for new arthritis in kids and young adults
This study follows children and young adults newly diagnosed with certain types of arthritis or related conditions to learn more about their health over time. It may help doctors better understand how these diseases progress and how treatments work.
BrusselsAges 2–50 - NCT06880653Recruiting
Exercise dose study for arthritis pain
This study looks at how different amounts of exercise affect arthritis symptoms. If you have arthritis or a related condition, you may be asked to try a specific weekly exercise goal to see if it helps your pain and mobility.
Columbia, South CarolinaAges 18 years+ - NCT06842316Recruiting
Study on cannabis-like compounds for inflammatory arthritis
This trial tests whether plant-based compounds similar to cannabis (called phytocannabinoids) can help calm inflammation and improve immune function in people with certain types of arthritis or autoimmune diseases like lupus or Sjögren's disease. It aims to offer a new way to treat these conditions without the 'high' of marijuana.
OrléansAges 18 years+ - NCT06826430RecruitingPhase 1
CAR-T cell therapy for severe lupus-related low platelets
This trial tests a new CAR-T cell treatment called Inaticabtagene Autoleucel for people with lupus that causes very low platelet counts (immune thrombocytopenia) that hasn't gotten better with standard treatments. The goal is to see if it can help raise platelet levels.
Beijing, Beijing MunicipalityAges 18–70 - NCT06828042RecruitingPhase 1/Phase 2
CAR-γδT cells for refractory autoimmune diseases
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets a protein called CD19 on your own B cells. It is for people with certain autoimmune diseases that have not gotten better with standard treatments. The goal is to see if this therapy can safely control the disease.
BeijingAges 18–80 - NCT06801119RecruitingPhase 1
HN2301 for autoimmune diseases study
This trial tests a new mRNA treatment called HN2301 for people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. It aims to see if the treatment is safe and helps control the disease.
Hefei, AnhuiAges 18–69 - NCT06795893Recruiting
Anifrolumab pregnancy outcomes study
This study collects information on pregnancy outcomes in women who took the drug anifrolumab during pregnancy or within 16 weeks before conception. It helps researchers understand how the drug may affect pregnancy and the baby.
SödertäljeAges Any age - NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT06775912RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
Lianyungang, JiangusAges 18–70 - NCT06763783Enrolling by invitationPhase 4
Shingles vaccine study for people with rheumatic diseases
This study offers the Shingrix shingles vaccine for free to adults with inflammatory rheumatic diseases. It compares how well the vaccine works in people taking immune-suppressing drugs versus those not taking them.
LundAges 18 years+ - NCT06659029Recruiting
Study on pregnancy outcomes in lupus patients using anifrolumab
This study tracks the health of pregnant women with moderate to severe lupus who have been treated with anifrolumab, compared to those treated with other lupus medications. It aims to understand how these treatments affect both mother and baby.
Wilmington, North CarolinaAges Any age - NCT06614270Recruiting
CAR-NK cell therapy for severe autoimmune diseases
This trial tests a new type of immune cell therapy using modified natural killer cells (CAR-NK) that target a protein called CD19 and produce helpful signals (IL-10 and IL-15). It is for people with certain autoimmune diseases that have not improved with standard treatments or have come back after getting better.
Hangzhou, ZhejiangAges 18–65 - NCT06594068RecruitingPhase 4
Anifrolumab in breastfeeding mothers with lupus
This study is looking at how the lupus medicine anifrolumab passes into breast milk and affects mothers and their babies. It is for women who are already taking anifrolumab for lupus and are breastfeeding a baby born at 32 weeks or later.
Las Vegas, NevadaAges 18–130 - NCT06599658RecruitingPhase 2
COVID-19 booster and flu vaccine timing for people with weak immune systems
This study tests the best timing for a COVID-19 booster and flu shot in people with weakened immune systems, such as organ transplant recipients, people living with HIV, or those with certain autoimmune conditions. It aims to help patients get better protection from both vaccines.
Montreal, QuebecAges 18 years+ - NCT06599411Recruiting
Skin biomarkers for inflammatory disease treatment
This study looks for clues in your skin and blood that could predict how well you'll respond to treatments for conditions like eczema, psoriasis, or lupus. It aims to help doctors choose the best therapy for you.
ParisAges 18 years+ - NCT06570798RecruitingPhase 2
Testing Two Drugs for Lupus and Rheumatoid Arthritis
This trial tests two study drugs, inebilizumab and blinatumomab, for people with lupus (SLE) or rheumatoid arthritis (RA) that hasn't gotten better with standard treatments. It focuses on those with active disease, especially lupus-related kidney problems.
Scottsdale, ArizonaAges 18–75 - NCT06557265RecruitingPhase 1/Phase 2
NKX019 for lupus kidney disease or membranous nephropathy
This trial tests an experimental cell therapy called NKX019 for people with active lupus nephritis (a type of kidney inflammation from lupus) or primary membranous nephropathy (another kidney condition) that hasn't gotten better after standard treatments. It may help if you have tried at least two treatments for lupus kidney disease or one for membranous nephropathy and still have active kidney disease.
Little Rock, ArkansasAges 18–75
Hear when a new Lupus or SLE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus or sle?
- Yes. Clin2 currently lists 333 recruiting lupus or sle studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus or sle trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus or sle trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.